---
title: "PPL: Q2 adjusted EBITDA up 5% year-over-year, with new assets and major projects fueling growth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294538495.md"
description: "Q2 2026 adjusted EBITDA rose 5% year-over-year to CAD 1.064 billion, with strong operational performance and new assets driving growth. Guidance for 2026 is reaffirmed, and major projects like Greenlight and Cedar LNG are advancing, supporting a robust long-term outlook.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-31T16:27:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294538495.md)
  - [en](https://longbridge.com/en/news/294538495.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294538495.md)
generator: "portal-rs"
---

# PPL: Q2 adjusted EBITDA up 5% year-over-year, with new assets and major projects fueling growth

Q2 2026 adjusted EBITDA rose 5% year-over-year to CAD 1.064 billion, with strong operational performance and new assets driving growth. Guidance for 2026 is reaffirmed, and major projects like Greenlight and Cedar LNG are advancing, supporting a robust long-term outlook.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [PBA.US](https://longbridge.com/en/quote/PBA.US.md)
- [PPL.US](https://longbridge.com/en/quote/PPL.US.md)
- [PPLC.US](https://longbridge.com/en/quote/PPLC.US.md)

## Related News & Research

- [Nvidia Expands AI Partnership With Amazon Web Services](https://longbridge.com/en/news/297671725.md)
- [ZAWYA: Accenture signs collaboration deal with AWS to boost Mideast cloud, data](https://longbridge.com/en/news/297674996.md)
- [MAI Capital hires ex-KeyBank, Bank of America executive Amy Brady as managing partner](https://longbridge.com/en/news/297680363.md)
- [QUICK SPARK: Microsoft's AI Spending Pays Off With Azure Growth Set to Reach 45%](https://longbridge.com/en/news/297673157.md)
- [ALMS: Envudeucitinib showed strong efficacy in IFNGS-high SLE patients and was well tolerated](https://longbridge.com/en/news/297666957.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**